Major histocompatibility complex class II (MHC II) molecules are central to adaptive immunity, presenting peptides derived from extracellular proteins to CD4+ T helper cells. Biosynthesis begins in ...

Which came first, MHC class I or MHC class II? For decades, it has been debated which of these two similar classes came first in evolution. Now, Keiichiro Hashimoto and his group at Fujita Health ...

Immunotherapies – treatments that aim to make the body's natural immune system more effective – are becoming more widely used ...

As the number of drugs with potential therapeutic use for T-cell-mediated diseases increases, there is a need to find methods of delivering such drugs to T cells. The major histocompatibility complex ...

Disparities in trends in bladder cancer mortality between urban and rural patients: A 2000-2020 analysis. This is an ASCO Meeting Abstract from the 2024 ASCO Annual Meeting I. This abstract does not ...

The study, according to the researchers, is the first to demonstrate the potential use of major histocompatibility complex class II (MHC-II) expression as a predictor of immunotherapy response in ...

Major histocompatibility complex class II (MHC-II) molecules play a critical, yet historically overlooked, role in tumor immunity. This review synthesizes emerging mechanistic evidence showing that ...

TACTI-004 trial evaluates efti with Keytruda and chemotherapy for advanced NSCLC, focusing on progression-free and overall survival. Efti's unique MHC Class 2 agonist mechanism shows strong efficacy ...

Analysis of primary and acquired resistance to cetuximab from multiomic data in the New EPOC trial. This is an ASCO Meeting Abstract from the 2023 ASCO Annual Meeting I. This abstract does not include ...

MHC-I presents peptides derived from endogenous antigens. Antigen is proteolyzed by the immune proteasome and specific peptides loaded to MHC-I. The resulting MHC-I–peptide complex is transported to ...